3759.HK in “Drug Manufacturing De-Risks From China”
Pharmaron Beijing Co., Ltd.
Its China-centered research outsourcing franchise faces slower orders as Western customers diversify vendors.
3759.HK impact map — “Drug Manufacturing De-Risks From China”
How this story travels from the headline to 3759.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 3759.HK impact map…
Price history, marked with story events
Sep 9, 2026 – Oct 19, 2026 · 29 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
Drug Manufacturing De-Risks From China
Western drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
BEAR side — Its China-centered research outsourcing franchise faces slower orders as Western customers diversify vendors.
Read the full Drug Manufacturing De-Risks From China story